Dexrazoxane for the treatment of chemotherapy-related side effects
Open accessThe DOI matches its Crossref record.
Abstract
For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ovarian damage from chemotherapy and current approaches to its protection
Spears, N., Lopes, F., Stefansdottir, A., Rossi, V, De Felici, M., Anderson, R. A., & Klinger, F. G. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz027 · Cited by 657
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention
Bhagat, A., & Kleinerman, E. S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_15 · Cited by 208
Repurposing approved drugs for cancer therapy
Schein, C. H. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldaa045 · Cited by 78
Intratumoral implantable drug delivery system for targeted localized chemotherapy in breast cancer
Souri, M., Elahi, S., & Soltani, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105519 · Cited by 31
Souri, M., Elahi, S., & Soltani, M. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2323211 · Cited by 28
Metadata
- Authors
- Langer, S.
- Venue
- Cancer Management and Research
- Publisher
- Informa UK Limited
- Published
- 2014-09
- Volume
- 6
- Pages
- 357
- ISSN
- 1179-1322 (ISSN-L)
- OpenAlex
- W2044450290
- Cited by
- 109
- References
- 0
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.